Clinical Trials Browser

Phase 2 × palbociclib × 1 year × Clear all

NCT02693535 2026-03-19

TAPUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT03573648 2026-03-19

ImmunoADAPT

Phase 2 Active not recruiting

Breast Neoplasms

NCT04439201 2026-03-19

Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)

Phase 2 Active not recruiting

40 enrolled 9 charts

LymphoidOther hematologic neoplasm

Lymphoma, Hematologic Neoplasms

NCT05554367 2026-03-18

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

Phase 2 Active not recruiting

GastrointestinalGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms

NCT05564377 2026-03-18

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Phase 2 Recruiting

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT06126276 2026-03-18

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

Phase 2 Recruiting

Other solid neoplasm

Malignant Female Reproductive System Neoplasm

NCT06390839 2026-03-17

Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)

Phase 2 Active not recruiting

43 enrolled 10 charts

Lymphoma

NCT02896335 2026-03-12

Palbociclib and Pembrolizumab In Central Nervous System Metastases

Phase 2 Recruiting

Brain Neoplasms

NCT03446157 2026-03-10

Palbociclib and Cetuximab in Metastatic Colorectal Cancer

Phase 2 Completed

24 enrolled 14 charts

Gastrointestinal

Colonic Neoplasms

NCT04931342 2026-03-10

BOUQUET

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT02905318 2026-03-09

Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03297606 2026-03-04

CAPTUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT07123090 2026-02-27

SPARCC

Phase 2 Not yet recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02778685 2026-02-24

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

Phase 2 Active not recruiting

47 enrolled 17 charts

Breast Neoplasms

NCT02624973 2026-02-12

PETREMAC

Phase 2 Active not recruiting

Breast Neoplasms

NCT03155620 2026-02-10

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Phase 2 Active not recruiting

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Xanthogranuloma, Juvenile, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Histiocytic Sarcoma

NCT02668666 2026-01-20

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

Phase 2 Completed

49 enrolled 14 charts

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT07299890 2025-12-23

An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer

Phase 2 Not yet recruiting

Breast Neoplasms

NCT05069038 2025-12-22

Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy

Phase 2 Active not recruiting

Breast Neoplasms

NCT04563507 2025-12-15

Combined Immunotherapies in Metastatic ER+ Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT02738866 2025-12-10

Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor

Phase 2 Active not recruiting

Breast Neoplasms

NCT01723774 2025-12-09

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Phase 2 Active not recruiting

84 enrolled 17 charts

Breast Neoplasms

NCT02630693 2025-11-25

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

Phase 2 Completed

180 enrolled 14 charts

Breast Neoplasms

NCT05226871 2025-11-25

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

Phase 2 Active not recruiting

BreastHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms

NCT06062498 2025-10-20

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT04567420 2025-10-16

DARE

Phase 2 Recruiting

Breast Neoplasms

NCT04438824 2025-10-14

Palbociclib and INCMGA00012 in People With Advanced Liposarcoma

Phase 2 Active not recruiting

Liposarcoma

NCT03147287 2025-09-30

Palbociclib After CDK and Endocrine Therapy (PACE)

Phase 2 Active not recruiting

220 enrolled 11 charts

Breast Neoplasms

NCT03535506 2025-09-26

WI223281

Phase 2 Terminated

17 enrolled 9 charts

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT07191977 2025-09-25

Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma

Phase 2 Not yet recruiting

Gastrointestinal

Esophageal Squamour Cell Cancer

NCT04553133 2025-08-28

PF-07104091 as a Single Agent and in Combination Therapy

Phase 2 Active not recruiting

BreastGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT01907607 2025-08-24

CYCLIGIST

Phase 2 Completed

29 enrolled 8 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT02730429 2025-07-31

Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer

Phase 2 Completed

Endometrial Neoplasms

NCT01356628 2025-07-28

A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer

Phase 2 Completed

23 enrolled 12 charts

Gastrointestinal

Liver Neoplasms

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT02764541 2025-05-07

Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)

Phase 2 Active not recruiting

195 enrolled 26 charts

Breast Neoplasms, Carcinoma, Lobular

NCT02040857 2025-04-29

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

Phase 2 Completed

162 enrolled 12 charts

Breast Neoplasms

NCT03389477 2025-04-13

Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma

Phase 2 Active not recruiting

26 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck